Register
|
Login
The Community Resource in Targeted Therapies
Driving Knowledge. Empowering Change. Optimizing Outcomes.
NEWS
CONFERENCES
VIDEOS
Case-Based Peer Perspectives
Expert Perspective Virtual Tumor Board
Interviews
Investigator Perspectives
Precision Medicine
PUBLICATIONS
Evolving Paradigms
Targeted Therapies in Oncology
The Journal of Targeted Therapies in Cancer
ONCAlert | Upfront Therapy for mRCC
Specialties >>
AML
Biomarker-Driven Lung Cancer
Bladder Cancer
Breast Cancer
CAR T-Cell Therapy
CLL
Colorectal Cancer
DLBCL
EGFR+ Lung Cancer
Follicular Lymphoma
Genomic Testing
GI Cancers
Gynecologic Cancers
HCC
Hematology
Immunotherapy
Leukemias
Lung Cancer
Lymphomas
Mantle Cell Lymphoma
Melanoma
MPNs
Multiple Myeloma
Prostate Cancer
Renal Cell Carcinoma
Skin Cancers
More >>
Partners >>
Dialogues in Diagnostics
Differential Diagnosis
Case-Based Peer Perspectives
Email Sign-Up
Targeted Therapies in Oncology
May 2015
Clinical Articles
Pan-Cancer Genetic Testing Provides Important Information for Identifying and Treating At-Risk Populations
JTT Articles
Participating Practices Commend CMS for OCM Changes
The Role of Liquid Biopsy in NSCLC Continues to Emerge
Rare Incidence of ICI-Related Hepatotoxicity Frequently Ends in Treatment Discontinuation
>> View Peer-Reviewed Articles
Most Popular
Updates Surrounding Leronlimab Use in Patients With COVID-19 Appear Promising
Enasidenib Granted FDA's Priority Review for IDH2-Mutant AML
Leronlimab Continues to Improve Health in Patients with Novel Coronavirus
Upfront Pembrolizumab With or Without Chemo Approved for HNSCC by FDA
